APA (7th ed.) Citation

T, S., J, P., A, A. R., P, L., KD, M., S, K., . . . A, T. (2024). First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors. Frontiers in oncology, 14, 1376551. https://doi.org/10.3389/fonc.2024.1376551

Chicago Style (17th ed.) Citation

T, Shimizu, et al. "First-in-human Phase 1 Dose-escalation Results with Livmoniplimab, an Antibody Targeting the GARP: TGF-ß1 Complex, as Monotherapy and in Combination with the Anti-PD-1 Antibody Budigalimab in Patients with Advanced Solid Tumors." Frontiers in Oncology 14 (2024): 1376551. https://doi.org/10.3389/fonc.2024.1376551.

MLA (9th ed.) Citation

T, Shimizu, et al. "First-in-human Phase 1 Dose-escalation Results with Livmoniplimab, an Antibody Targeting the GARP: TGF-ß1 Complex, as Monotherapy and in Combination with the Anti-PD-1 Antibody Budigalimab in Patients with Advanced Solid Tumors." Frontiers in Oncology, vol. 14, 2024, p. 1376551, https://doi.org/10.3389/fonc.2024.1376551.